Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1809 results
September 2020
-
Media Release
Novartis announces NEJM publication of pivotal study of Tabrecta™ in patients with METex14 metastatic non-small cell lung cancer
Tabrecta™ (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon… -
Statement
AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy
-
Featured News
Bold Advocates for Blood Cancers and Blood Disorders
Blood diseases place a huge burden on individual patients, their families and on wider society. Yet advances in hematology treatment give so much cause for hope. It’s our responsibility to turn that hope into reality. Hear from five bold advocates who inspire us.
-
Media Release
New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines
The collaboration aims to help alleviate supply and logistical constraints in the African Union member states Portfolio of 15 generic and over-the-counter (OTC) medicines from Sandoz division… -
Key Release
Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality
2025 target to increase patients reached in LMICs with strategic innovative medicines by 200% and the Novartis Flagship Programs by 50% - bringing potential reach to over 23 million patients across…
August 2020
-
Story Discovery
Guidance system lights a path for drug discovery
Novartis drug hunters leverage machine learning and automation to power a faster, smarter way to navigate to new drugs.
-
Media Release
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran
Pooled data from Phase III ORION-10 and -11 showed highly consistent efficacy, tolerability and safety profile over 17 months on twice-yearly subcutaneous dosing in 2,300 patients (of which 1,164… -
Media Release
Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH)
Oral, investigational complement factor B inhibitor LNP023 substantially improved hematological response as add-on therapy to eculizumab Seven of ten patients discontinued eculizumab and remained on… -
In The News
Supply chain organization during the COVID-19 pandemic
Balancing priorities of combating the crisis and ongoing trials. -
Featured News
50 Climate Leaders
At Novartis, we aim to be a leader in environmental sustainability and a catalyst for positive change both in our own operations and in our supply chain.
-
Media Release
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
At primary analysis, ASCEMBL met its primary endpoint of significant superiority in major molecular response rate at 24 weeks for asciminib (ABL001) vs. bosutinib in patients previously treated with… -
In The News
The coronavirus is giving health and pharma companies a chance to woo tech talent
Novartis Chief Digital Officer Bertrand Bodson says tech professionals don’t need a background in biology to switch industries.